Phase 2
N=119
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Atopic Dermatitis Eczema
Bottom Line
View on ClinicalTrials.gov: NCT05579899 ↗Enrolled (actual)
119
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 — -43.5; -62.0 Percent change from baseline
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- EVO101 (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Evommune, Inc.
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 |
-43.5; -62.0 | — |
| SECONDARY Investigator Global Assessment (IGA) Response (Number of Participants With >= 2 Points Change From Baseline to Week 8) |
20; 23; 37; 28 | — |
| SECONDARY Percent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8 |
-2.1; -3.5 | — |
| SECONDARY Pruritus-NRS, Change From Baseline to Week 8 |
-2.5; -3.5 | — |
Summary
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
Eligibility Criteria
Inclusion Criteria
- Males or non-pregnant, non-lactating females, age 18 years or older
- Chronic atopic dermatitis for at least 1 year
- IGA score of 2 or 3
- BSA of AD involvement of 4-12%
- EASI of 5-20
Exclusion Criteria
- Significant AD flare with 4 weeks
- Use of biologic therapy within 12 weeks
- Regular use of tanning booth within 4 weeks
- Skin condition that could interfere with study assessments
Data sourced from ClinicalTrials.gov (NCT05579899). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.